NEW YORK (TheStreet) -- Shares of Allergan (AGN) were edging lower in late afternoon trading on Tuesday ahead of the company's 2016 third quarter report, due before the opening bell on Wednesday.

Analysts surveyed by FactSet are looking for the Dublin-based pharmaceutical company to post adjusted earnings of $3.56 per share on revenue of $3.71 billion for the quarter.

In the same period last year, Allergan reported adjusted earnings of $3.48 per share on revenue of $4.09 billion.

Barclays said yesterday that the Allergan has a number of durable growth assets like its Botox drug.

But the company also has many "mature" assets, the firm noted, adding that Wall Street's estimates for growth in 2017 and 2018 are too high.

The firm reinstated coverage of the stock with an "equal weight" rating and $250 price target.

(Allergan is held in Jim Cramer's charitable trust Action Alerts PLUS. See all of his holdings with a free trial.)

Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

TheStreet Ratings rated this stock as a "hold" with a ratings score of C.

The company's strengths can be seen in multiple areas, such as its growth in earnings per share, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and a generally disappointing performance in the stock itself.

You can view the full analysis from the report here: AGN


More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing